8-K: Predictive Oncology Reports Q2 2024 Results, Expands into Biomarker Discovery

Predictive Oncology announced its second quarter 2024 financial results, highlighted by a strategic shift into biomarker discovery and a cost-saving initiative.

Summary

• Predictive Oncology reported a net loss of approximately $3.2 million on revenue of approximately $0.3 million for the second quarter of 2024.
• The company has entered the biomarker discovery market, leveraging its AI/ML capabilities and tumor sample biorepository.
• A cost savings initiative is expected to reduce the company's cash burn by approximately 20% annually when fully implemented in Q4 2024.
• The company ended the quarter with $5.3 million in cash and cash equivalents, down from $8.7 million at the end of 2023.
• The company raised $3.1 million through its at-the-market facility and an additional $1.3 million through warrant exercises.
• The company's basic and diluted net loss per common share for the quarter was $(0.68), compared to $(0.98) for the same period last year.
• Revenue for the quarter was $278,722, compared to $490,110 for the same period in 2023, primarily due to decreased sales of STREAMWAY systems.
• Gross profit margin decreased to approximately 45% from 67% in the prior year due to increased labor costs and a change in sales mix.
• General and administrative expenses decreased to $2.1 million from $2.7 million in the prior year, primarily due to decreased employee compensation and investor relations costs.
• The company is consolidating its Birmingham laboratory operations into its Pittsburgh facility.

Sentiment

Score: 5

Explanation: The company is making a strategic shift into a high-growth market, but its current financial performance is weak. The cost savings initiative is a positive, but the company's cash burn is a concern.

Positives

• The company has successfully entered the biomarker discovery market, a significant growth opportunity.
• The company's AI/ML models have shown promising results in predicting ovarian cancer patient outcomes.
• The cost savings initiative is expected to significantly reduce cash burn.
• The company has secured new collaborations to expand its research capabilities.
• The company has raised additional capital through its at-the-market facility and warrant exercises.
• The net loss per share improved compared to the same quarter last year.

Negatives

• The company reported a net loss of approximately $3.2 million for the quarter.
• Revenue decreased to $278,722 from $490,110 in the same quarter last year.
• Gross profit margin decreased to 45% from 67% in the prior year.
• The company's cash balance decreased from $8.7 million at the end of 2023 to $5.3 million at the end of Q2 2024.

Risks

• The company's future performance may be affected by the success of its collaboration arrangements and commercialization activities.
• The company's ability to achieve its projected cost savings may be impacted by unforeseen challenges.
• The company's ability to generate revenue from its new biomarker discovery initiatives is uncertain.
• The company's cash reserves are decreasing, which may require additional capital raises in the future.

Future Outlook

The company is focused on expanding its biomarker discovery efforts and implementing cost savings initiatives to extend its cash runway. The company expects to be a leader in the application of artificial intelligence and machine learning toward biomarker discovery.

Management Comments

• The clear highlight since our last quarterly update is our announcement just a few weeks ago that we have expanded our AI/ML offering to pursue the discovery of novel biomarkers capable of predicting patient outcomes and drug responses, beginning with ovarian cancer.
• The ability to identify biomarkers, in addition to validating existing biomarkers, means that we are now one step closer to discovering our own biomarkers that we can further develop, either independently or with a partner.
• This will allow us to be a more active participant in drug discovery and enable us to play a key role in the development of the next generation of cancer therapeutics, all with our existing resources.
• To ensure that we are well positioned to capitalize on this and other opportunities as they emerge, we also recently announced a strategic cost savings initiative designed to streamline our operations and extend our cash runway.
• Given the importance of biomarkers in drug discovery and development, we are working tirelessly to be a leader in the application of artificial intelligence and machine learning toward this goal.

Industry Context

The company's move into biomarker discovery aligns with the growing trend of using AI and machine learning in drug development. The biomarker discovery market is estimated to be a significant opportunity, and Predictive Oncology is positioning itself to capitalize on this trend.

Comparison to Industry Standards

• Predictive Oncology's revenue of $0.3 million for the quarter is low compared to established biotech companies, which often report tens or hundreds of millions in revenue.
• The company's net loss of $3.2 million is typical for early-stage biotech companies focused on research and development.
• The company's gross profit margin of 45% is lower than the industry average for biotech companies, which often have margins above 60%.
• The company's cash balance of $5.3 million is relatively low and may require additional capital raises in the near future. Companies like Veracyte (VCYT) and Exact Sciences (EXAS) have significantly higher cash reserves.
• The company's focus on AI/ML for biomarker discovery is in line with industry trends, but its success will depend on its ability to generate revenue from this new focus. Companies like Recursion Pharmaceuticals (RXRX) are also leveraging AI/ML in drug discovery.

Stakeholder Impact

• Shareholders may be concerned about the company's net loss and decreasing cash balance.
• Employees may be affected by the cost savings initiative, including the consolidation of the Birmingham laboratory.
• Customers may benefit from the company's new biomarker discovery capabilities and 3D cell culture models.
• Suppliers may be impacted by the company's cost savings initiative.

Next Steps

• The company will continue to develop its biomarker discovery capabilities.
• The company will implement its cost savings initiative.
• The company will explore partnerships for biomarker development.
• The company will continue to evaluate the viability of migrating revenue-generating activities from Birmingham to Pittsburgh.

Key Dates

Keywords

biomarker discovery, artificial intelligence, machine learning, oncology, drug discovery, cancer therapeutics, cost savings, financial results, net loss, revenue, cash runway